



2009 Advances in
**INFLAMMATORY
BOWEL DISEASES**

Crohn's & Colitis Foundation's
Clinical & Research Conference

December 3 – 6, 2009, Hollywood, Florida

ACCEPTED ABSTRACTS

We would like to congratulate the winners of the 2009 Abstract Awards:

Best Research Abstract: Tara Willson, BS –Cincinnati, OH, USA

Best Clinical Abstract: Sandra El-Hachem, MD –Pittsburgh, PA, USA

Best Overall Abstract: Elke Cario, MD –Essen, Germany

Young Investigator Award : Bodo Grimbacher –London, UK

Table of Contents

CLINICAL

O-0001. Analysis of secular trends and impact of Clostridium difficile in hospitalized children with inflammatory bowel disease

Nylund C^{1,2}, Denson L¹

¹Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, ²Air Force Institute of Technology, Wright Patterson Air Force Base, Ohio

O-0002. Is Isotretinoin exposure associated with Inflammatory Bowel Disease? A Case Control Study

Crockett S¹, Porter C², Kappelman M³

¹Division of Gastroenterology and Hepatology, Department of Medicine, University of North Carolina at Chapel Hill, NC, USA, ²Cecil G. Sheps Center for Health Services Research, University of North Carolina at Chapel Hill, NC, USA, ³Division of Gastroenterology, Department of Pediatrics, University of North Carolina at Chapel Hill, NC, USA

O-0003. Need for rescue therapy in IBD patients on infliximab maintenance therapy after discontinuation of immunomodulator

Fischer M, Helper D, Chiorean M, Juliar B

Indiana University, Indianapolis, IN, USA

O-0004. The association between IBD and Venous Thromboembolic Events in Danish children and adults: A population-based case-control study

Kappelman M¹, Puho E², Sandler R¹, Rubin D³, Ullman T⁴, Pederson L², Baron J⁵, Sorensen H²

¹University of North Carolina, Chapel Hill, NC, USA, ²Aarhus University, Aarhus, Denmark, ³University of Chicago, Chicago, IL, USA, ⁴Mount Sinai School of Medicine, New York, NY, USA, ⁵Dartmouth Medical School, Hanover, NH, USA

O-0005A. Relationship between depressive severity and demographics in youth with Inflammatory Bowel Disease

Karwowski C¹, Richardson A¹, Kirshner M¹, Ducharme P², Fairclough D³, Keljo D¹, Bousvaros A², Gonzales-Heydrich J², Szigethy E¹

¹Children's Hospital of Pittsburgh, PA, USA, ²Children's Hospital Boston, Boston MA, USA, ³University of Colorado at Denver, Denver CO, USA

O-0005B. Characterizing depression in children with Inflammatory Bowel Disease

Karwowski C¹, Richardson A¹, Kirshner M¹, Ducharme P², Fairclough D³, Keljo D¹, Bousvaros A², Gonzales-Heydrich J², Szigethy E¹

¹Children's Hospital of Pittsburgh, Pittsburgh, PA, USA, ²Children's Hospital Boston, Boston, MA, USA, ³University of Colorado at Denver, Denver, CO, USA

O-0006. Improved outcomes in a quality improvement collaborative for Pediatric Crohn Disease

Crandall W, Kappelman M, Colletti R, Denson L, Duffy L, Grunow J, Kim S, Leibowitz I, Patel A, Schoen B, Tomer G, Milov D, Cohen S, Margolis P

The ImproveCareNow Collaborative (formerly PIBDNet), Burlington, VT, USA

O-0007. Immunogenicity of influenza vaccination in children with Inflammatory Bowel Disease

deBruyn J^{1,2}, Hilsden R², Wrobel I^{1,2}

¹Alberta Children's Hospital, Calgary, Alberta, Canada, ²University of Calgary, Calgary, Alberta, Canada

P-0001. Probiotics marketed to patients with Crohn's Disease lack supporting data

Adham K, Dougherty T, Sardana N, Prakash P, Borum M

George Washington University, Washington, DC, USA

P-0002. Fistulizing Pouchitis: A role for Biologics?

Alsheik E¹, Zuchelli T¹, Bhandari B²

¹Drexel University College of Medicine, Philadelphia, PA, ²Division of Gastroenterology and Hepatology, Drexel University College of Medicine, Philadelphia, PA, USA

P-0003. Metronidazole failure in treatment of community acquired Clostridium Difficile Colitis in Inflammatory Bowel Disease patients: A Case Series

Bakshi A, Prakash P, Chandler M, Borum M

George Washington University, Washington, DC, USA

P-0004. Refractory Clostridium difficile infection masking undiagnosed ulcerative colitis

Bollinger E¹, Martinez J¹, Pollack S², Ruiz B³

¹LSUHSC New Orleans Department of Medicine, New Orleans, LA, USA, ²Tulane University Department of Gastroenterology, New Orleans, LA, USA, ³LSUHSC New Orleans Department of Pathology, New Orleans, LA, USA

P-0005. Prompt and highly effective control of severe abdominal pain and dyschezia with sympathomimetic amine therapy in a woman with Crohn's disease resistant to standard therapy

Check J, Katsoff B, Cohen R

UMDNJ, Robert Wood Johnson Med. School at Camden, Marlton, NJ

P-0006. Metastatic Crohn's Disease of the vulva and perineum treated with Anti-mycobacterial Therapy

Dave A, Wasserman J, Shea C, Rubin D

Inflammatory Bowel Disease Center, University of Chicago Medical Center, Chicago, IL, USA

P-0007. The role of cytomegalovirus infection in refractory ulcerative colitis: A case report

Ezmerli N^{1,2}, Lipman T², Liu M²

¹Georgetown University Hospital, Washington, DC, USA, ²Veterans Affairs Medical Center, Washington, DC, USA

P-0008. Myeloproliferative disorder in patients with Inflammatory Bowel Disease on Anti-TNF- α Therapy: Report of two cases and review of the literature

Fischer M, Helper D, Chiorean M

Indiana University, Indianapolis, IN, USA

P-0009. Acute pancreatitis within hours of 6-mercaptopurine use

Homenko D, Viveiros K

Tufts Medical Center, Boston, MA, USA

P-0010. Venous sinus thrombosis in a child with ulcerative colitis

Jibaly R, Kaddourah A

Michigan State University, Grandblanc, MI, USA

P-0011. Granulomatous Hepatitis and Acalculus Cholecystitis in an adolescent male with newly diagnosed Crohn's Disease: A Case Report

Kahana D¹, Jiyamapa J², Vasinrapee P², French S³, Gershman G¹

¹Department of Pediatrics, Harbor-UCLA Medical Center, Torrance, CA, USA, ²Department of Radiology, Harbor-UCLA Medical Center, Torrance, CA, USA, ³Department of Pathology, Harbor-UCLA Medical Center, Torrance, CA, USA

P-0012. Inflammatory bowel diseases in the young child

Kelly M, Lichtman S, Kappelman M

UNC-CH Department of Pediatrics, Chapel Hill, NC

P-0013. Mycobacterium intracellulare pulmonary infection in an immunosuppressed child with Crohn's Disease

Lee Y¹, Kim K¹, Jang J², Rhee K¹

¹Division of Pediatric Gastroenterology and Nutrition, Department of Pediatrics, Asan Medical Center Children's Hospital, University of Ulsan College of medicine, Seoul, Korea, ²Department of Pediatrics, Ajou University School of Medicine, Youngtong-gu, Suwon, Korea

P-0014. Exacerbation of Ulcerative Colitis after switching from Asacol to Lialda: A case report

Mangold M, Merikhi L, Ahmad A

Drexel University/Hahnemann Hospital, Philadelphia, PA., USA

P-0015. Suicidal ideation resulting from severe Inflammatory Bowel Disease symptoms

Okoji O, Zeddun S, Borum M

George Washington University, Washington, DC, USA

P-0016. Vitiligo may be associated with Inflammatory Bowel Disease

Shafa S, Borum M

George Washington University, Washington, DC, USA

P-0017. Does Combination Therapy using Rifaximin with Adalimumab improve Crohn's Disease activity and Mucosal Healing? A Case Series

Shafran I, Burgunder P

Shafran Gastroenterology Center, Winter Park, FL, USA.

P-0018. Severe neutropenia following a single infliximab infusion in a child with Crohn disease

Sherlock M, Bandsma R, Ota K, Kirby-Allen M, Griffiths A

The Hospital for Sick Children, Toronto, Canada

P-0019. Dysregulation of Arachidonic Acid Metabolism resulting from Aminosalicilate administration may cause Asthma Exacerbation in atopic patients with Inflammatory Bowel Disease

Siegel N, Borum M

George Washington University, Washington, DC, USA

P-0020. Characteristics of pediatric patients with Crohn's Disease presenting with chronic constipation: A Case Series

Tennyson L¹, Quiros J^{1 and 2}, Quan R¹

¹UCDMC, Sacramento, CA, USA, ²CPMC

P-0021. Hepatosplenic T cell Lymphoma following exposure to Infliximab in a patient with ulcerative colitis.

Wijeratne R, Teller T, Sekhon H, Abbas M

Kaiser Permanente, Los Angeles, CA, USA

P-0022. PROTECT-1 Maintenance Phase Study Results demonstrate efficacy of the Intestine-Specific Chemokine Receptor Antagonist CCX282-B (Traficet-EN) in Crohn's Disease

Bekker P¹, Keshav S², Johnson D¹, Schall T¹

¹ChemoCentryx, Inc., Mountain View, CA, USA, ²John Radcliffe Hospital, Oxford, UK

P-0023. Long-term follow-up of patients enrolled in the Randomized Controlled Trial (RCT) of Infliximab for prevention of recurrent Crohn's Disease (CD)

EI-Hachem S, Regueiro M, Kevin K, Schraut W, Baidoo L, Harrison J, Pesci M, Watson A, Binion D

University of Pittsburgh Medical Center, Pittsburgh, PA

P-0024. Infliximab initiated shortly after Crohn's Disease (CD) Resection is not associated with increased adverse events

EI-Hachem S, Regueiro M, Schraut W, Baidoo L, Kip K, Plevy S, Watson A, Harrison J, Pesci M, Binion D

University of Pittsburgh Medical Center, Pittsburgh, PA, USA

P-0025. Emerging Safety Profile of Vedolizumab: A novel, selective Integrin Inhibitor for the treatment of IBD Feagan B¹, Leach T², Milch C², Parikh A², Fox I²

¹Robarts Clinical Trials, Robarts Research Institute, London, Ontario, Canada; University of Western Ontario, London, Ontario, Canada, ²Millennium Pharmaceuticals, Inc. Cambridge MA, USA

P-0026. Asthma, allergies, and...Crohn's? Oh, my!

Moreau J, Khuntia A, Wolf R

University of Chicago Comer Children's Hospital, Chicago, IL, USA

P-0027. Long-term remission with certolizumab pegol in Crohn's disease over 3.5 years: results from the PRECiSE 3 study

Lichtenstein G¹, Thomsen O², Schreiber S³, Lawrance I⁴, Hanauer S⁵, Bloomfield R⁶, Sandborn W⁷

¹University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, USA, ²Herlev Hospital, University of Copenhagen, Copenhagen, Denmark, ³Hospital for General Internal Medicine, Christian Albrechts University, Kiel, Germany, ⁴School of Medicine and Pharmacology, University of Western Australia, Fremantle Hospital, Fremantle, Australia, ⁵University of Chicago Medical Center, Chicago, USA, ⁶UCB Pharma, Slough, Berkshire, UK, ⁷Mayo Clinic, Rochester, Minnesota, USA

P-0028. Sustained Mucosal Healing in Adalimumab-Treated patients with moderate to severe Ileocolonic Crohn's Disease: Results of the EXTEND Trial

Rutgeerts P¹, D'Haens G², van Assche G¹, Sandborn W³, Wolf D⁴, Colombel J⁵, Reinisch W⁶, Geboes K⁷, Khan M⁸, Lazar A⁹, Camez A⁹, Pollack P⁸

¹University Hospital of Gasthuisberg, Leuven, Belgium, ²Imelda GI Clinical Research Center, Bonheiden, Belgium, ³Mayo Clinic, Rochester, MN, USA, ⁴Atlanta Gastroenterology Associates, Atlanta, GA, USA, ⁵Hôpital Claude Huriez, Centre Hospitalier Universitaire de Lille, Lille, France, ⁶Medical University of Vienna, Vienna, Austria, ⁷University Hospital of the KULeuven, Leuven, Belgium, ⁸Abbott Laboratories, Abbott Park, IL, USA, ⁹Abbott GmbH & Co. KG, Ludwigshafen, Germany

P-0029. SONIC Study: A Randomized, Double-Blind Trial Comparing Infliximab and Infliximab plus Azathioprine to Azathioprine in Patients with Crohn's Disease Naïve to Immunomodulators and Biologic Therapy

Sandborn W¹, Rutgeerts P², Reinisch W³, Mantzaris G⁴, Kornbluth A⁵, Rachmilewitz D⁶, Lichtiger S⁵, D'Haens G⁷, van der Woude C⁸, Diamond R⁹, Broussard D⁹, Tang K⁹, Colombel J¹⁰

¹Mayo Clinic, Rochester, MN., USA, ²U Hosp, Gasthuisberg, Leuven, Belgium, ³U Hosp Vienna, Vienna, Austria, ⁴Evangelismos Hospital, Athens, Greece, ⁵Mt Sinai Medical Ctr, New York, NY, USA, ⁶Shaare Zedek Medical Ctr, Jerusalem, Israel, ⁷Imelda Ziekenhuis, Bonheiden, Belgium, ⁸Erasmus MC Rotterdam, Netherlands, ⁹Centocor, Inc., Horsham, PA., USA, ¹⁰Centre Hospitalier Universitaire de Lille, France

P-0030. Efficacy of certolizumab pegol is not affected by baseline anti-infliximab antibody status in patients with Crohn's disease with secondary infliximab failure

Sandborn W¹, Vermeire S², D'Haens G³, Colombel J⁴, Fedorak R⁵, Spehlmann M⁶, Wolf D⁷, Mitchev K⁸, Jamoul C⁸, Abreu M⁹, Rutgeerts P²

¹Gastroenterology & Hepatology, Mayo Clinic, Rochester, MN, USA, ²Gastroenterology, University Hospital Gasthuisberg, Leuven, Belgium, ³Gastroenterology, Imelda General Hospital, Bonheiden, Belgium, ⁴Hepatogastroenterology, CHU Lille, Lille, France, ⁵Gastroenterology, University of Alberta, Edmonton, AB, Canada, ⁶Department of Medicine, University of California, San Diego, CA, USA, ⁷Atlanta Gastroenterology Associates, Atlanta, GA, USA, ⁸UCB, Braine l'Alleud, Belgium, ⁹Gastroenterology, University of Miami, Miami, FL, USA

P-0031. Long-term maintenance of remission with no dose escalation after re-induction with certolizumab pegol in patients with Crohn's disease exacerbation: 3-year results from the PRECiSE 4 study

Sandborn W¹, Schreiber S², Hanauer S³, Colombel J⁴, Bloomfield R⁵, Lichtenstein G⁶

¹Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN, USA, ²Institute for Clinical Molecular Biology, Christian Albrechts University, Kiel, Germany, ³Department of Gastroenterology and Nutrition, University of

Chicago Medical Center, Chicago, IL, USA, ⁴Hepato-Gastroenterologie, Hôpital Claude Huriez, Lille, France, ⁵UCB Pharma, Slough, UK, ⁶University of Pennsylvania School of Medicine, Philadelphia, PA, USA

P-0032. Rapid symptom resolution with delayed-release Mesalamine 4.8g/d compared to 2.4g/d in moderately active Ulcerative Colitis patients with a history of more difficult to treat disease

Sandborn W¹, Ramsey D², Sninsky C³

¹Mayo Clinic, Rochester, MN, USA, ²Procter & Gamble Pharmaceuticals, Mason, OH, USA, ³Digestive Disease Associates, Gainesville, FL, USA

P-0033. Once daily dosing of delayed-release oral mesalamine for maintenance of remission of Ulcerative Colitis (the QDIEM Trial): 6 and 12 month results

Sandborn W¹, Kane S¹, Korzenik J², Lashner B³, Leighton J⁴, Mahadevan U⁵, Marion J⁶, Safdi M⁷, Sninsky C⁸, Ramsey D⁹

¹Mayo Clinic, Rochester, MN, USA, ²Massachusetts General Hospital, Boston, MA, USA, ³Cleveland Clinic, Cleveland, OH, USA, ⁴Mayo Clinic Arizona, Scottsdale, AZ, USA, ⁵UCSF Center-Colitis and Crohn's Disease, San Francisco, CA, USA, ⁶Mt. Sinai School of Medicine, New York, NY, USA, ⁷Ohio Gastroenterology and Liver Institute, Cincinnati, OH, USA, ⁸Digestive Disease Associates, Gainesville, FL, USA, ⁹Procter & Gamble Pharmaceuticals, Mason, OH, USA

P-0034. Rapid improvement of patient-reported CDAI diary components by day 8 in active Crohn's disease patients treated with certolizumab pegol

Schreiber S¹, Khaliq-Kareemi M², Lawrance I³, Thomsen O⁴, Bloomfield R⁵, Sandborn W⁶

¹Christian Albrechts University, Kiel, Germany, ²Alberta Health Services, Calgary, AB, Canada, ³Fremantle Hospital, Fremantle, Western Australia, Australia, ⁴Herlev Hospital, Copenhagen, Denmark, ⁵UCB Celltech, Slough, UK, ⁶Mayo Clinic, Rochester, MN, USA

P-0035. Efficacy of certolizumab pegol in Crohn's disease patients with secondary failure to infliximab is not affected by concomittant medications

Sandborn W¹, Vermerie S², Abreu M³, D'Haens G⁴, Colombel J⁵, Mitchev K⁶, Jamoul C⁶, Fedorak R⁷, Spehlmann M⁸, Wolf D⁹, Lee S¹⁰, Rutgeerts P²

¹Gastroenterology & Hepatology, Mayo Clinic, Rochester, MN, USA, ²Gastroenterology, University Hospital Gasthuisberg, Leuven, Belgium, ³Gastroenterology, University of Miami, Miami, FL, USA, ⁴Gastroenterology, Imelda General Hospital, Bonheiden, Belgium, ⁵Hepatogastroenterology, CHU Lille, Lille, France, ⁶UCB, Braine l'Alleud, Belgium, ⁷Gastroenterology, University of Alberta, Edmonton, AB, Canada, ⁸Department of Medicine, University of California, San Diego, CA, USA, ⁹Atlanta Gastroenterology Associates, Atlanta, GA, USA, ¹⁰Gastroenterology, University of Washington School of Medicine, Seattle, WA, USA

P-0036. Oral glutamine supplementation in Inflammatory Bowel Disease patients: Quality of life matters

Wurzer H¹, **Steindl G¹**, Gombotz G¹, Schimetta W²

¹LKH Feldbach, Austria, ²Applied Systems Research and Statistics, University of Linz, Austria

P-0037. The Role of SAHA for Preventing IL-13-Induced Colon Epithelial Cell Dysfunction

Rosen M, Washington M, Polk D

Vanderbilt University School of Medicine, Nashville, TN, USA

P-0038. Determinants of corticosteroid-resistance in severe pediatric ulcerative colitis

Turner D¹, Wine E², Kolho K³, Mack D⁴, Hyams J⁵, Silverberg M⁶, Otle A⁷, Markowitz J⁸, Crandall W⁹, Leleiko N¹⁰, Griffiths A²

¹Shaare Zedek Medical Center, Jerusalem, Israel, ²The Hospital for Sick Children, Toronto, On, Canada, ³Hospital for Children and Adolescents, Helsinki, Finland, ⁴CHEO, Ottawa, On, Canada, ⁵Connecticut Children's Medical Center, Hartford, Connecticut, USA, ⁶Mount Sinai Hospital, Toronto, On, Canada, ⁷IWK, Halifax, NS, Canada, ⁸Schneider's Children's Hospital, Long Island, New York, USA, ⁹Nationwide Children's Hospital, Columbus, Ohio, USA, ¹⁰Brown University, Providence, Rhode Island, USA

P-0039. Spectrum of risk factors associated with Osteoporosis in patients with Inflammatory Bowel Disorders in an inner city hospital population

Anna K, Periyalwar P, Sappati Biyyani R, Putka B

Case Western Reserve University(Metrohealth),Cleveland ,OH, USA

P-0040. Phenotypic variables associated with progression of disease behaviour In Crohn's Disease

Halder S¹, Sharaf A¹, Stempak J¹, Nguyen G¹, Greenberg G¹, Xu W², Steinhart H¹, Silverberg M¹

¹Mount Sinai Hospital, Toronto, ON, Canada, ²Biostatistics Division, University of Toronto, Toronto, ON, Canada

P-0041. A short pediatric Crohn's Disease Activity Index for Quality Improvement and Observational Research

Kappelman M, Crandall W, Colletti R, Leibowitz I, Duffy L, Milov D, Kim S, Schoen B, Patel A, Grunow J, Goudie A, Larry E, Fairbrother G, Margolis P

The ImproveCareNow Collaborative (formerly PIBDNet), Burlington, VT, USA.

P-0042. The UNC T.RxA.N.S.I.T.I.O.N. Scale™: A tool to measure the process of health care transition for adolescent IBD patients

Kelly M^{1,2}, Ferris M^{1,3}, Ford C^{1,4}, Bickford K^{1,3}, Layton B^{1,3}, Kim S^{1,2}

¹UNC-CH Department of Pediatrics, Chapel Hill, NC, USA, ²UNC-CH Division of Gastroenterology, Chapel Hill, NC, USA, ³UNC-CH Kidney Center, Chapel Hill, NC, USA, ⁴UNC-CH Division of General Pediatrics, Chapel Hill, NC, USA

P-0043. Describing characteristics and chronology of Crohn's Disease in African Americans

Malik T, Oster R, Eckhoff A, Gutierrez A

University of Alabama at Birmingham, AL, USA

P-0044. Impaired muscle function and tibial bone deficits in children with Crohn's Disease

Ward L¹, Rauch F², Mack D¹

¹Department of Pediatrics, Children's Hospital of Eastern Ontario, University of Ottawa, Ottawa, Ontario, Canada,

²Department of Pediatrics, Shriners Hospital for Children, McGill University, Montréal, Québec, Canada

P-0045. Assessment of Anti-TNF dosing patterns in adults with Crohn's Disease

Waters H¹, Gomez Rey G², Chastek B²

¹Centocor Ortho Biotech Services, LLC, Horsham, PA., USA, ²i3 Innovus, Health Economics and Outcomes, Eden Prairie, MN., USA

P-0046. Stability of Infliximab dosing in Crohn's disease: Results from a Chart Review

Waters H¹, McKenzie R¹, Lunacsek O², Franklin M², Lennert B², Piech C¹

¹Centocor Ortho Biotech Services, LLC, Horsham, PA., USA, ²Xcenda LLC, Palm Harbor, FL., USA

P-0047. Low income children with Inflammatory Bowel Disease have higher surgical and hospitalization rates in a Universal Health Care System

Benchimol E^{1,2}, To T^{1,2}, Griffiths A², Rabeneck L³, Guttman A^{1,2}

¹The Institute for Clinical Evaluative Sciences, Toronto, ON, Canada, ²The Hospital for Sick Children, Toronto, ON, Canada, ³Sunnybrook Health Sciences Centre, Toronto, ON, Canada

P-0048. The perceptions of risks and benefits of Infliximab and Leukocytapheresis by Japanese patients with Inflammatory Bowel Disease

Fukunaga K¹, Matsumoto T¹, Matsui T², Fujiyama Y³, Takayama T⁴, Ashida T⁵, Kohgo Y⁶, Hibi T⁷, Watanabe M⁸

¹Hyogo College of Medicine, Dept of Gastroenterology, Hyogo Japan, ²Fukuoka University Faculty of Medicine, Dept of Gastroenterology, Fukuoka, Japan, ³Shiga University of Medical Science, Dept of Gastroenterology, Shiga, Japan,

⁴Faculty of Medicine, The University of Tokushima, Dept of Gastroenterology, Tokushima, Japan, ⁵Sapporo-higashi Tokusyukai Hospital, IBD center, Sapporo, Hokkaido, Japan, ⁶Asahikawa Medical College, Dept of Gastroenterology & Hematology (Oncology), Asahikawa, Hokkaido, Japan, ⁷School of Medicine, Keio University, Dept of

Gastroenterology, Tokyo, Japan, ⁸Tokyo Medical and Dental University, Dept of Gastroenterology, Tokyo, Japan

P-0049. Factors Associated with recurrent intestinal resection in Pediatric patients with Crohn's Disease

Gupta N¹, Glidden D², Cohen S^{3,4}, Baldassano R⁵, Gold B³, Kirschner B⁶, Ferry G⁷, Durant M⁸, Winter H⁹, Smith T⁷, Heyman M¹

¹UCSF Children's Hospital, University of California, San Francisco, CA, USA, ²Department of Epidemiology and Biostatistics, University of California, San Francisco, CA, USA, ³Children's Center for Digestive Healthcare, Children's Healthcare of Atlanta, Atlanta, GA, USA, ⁴Emory University School of Medicine, Atlanta, GA, USA, ⁵The Children's Hospital of Philadelphia, Philadelphia, PA, USA, ⁶The University of Chicago Comer Children's Hospital, Chicago, IL, USA, ⁷Texas Children's Hospital, Baylor College of Medicine, Houston, TX, USA, ⁸Kaiser Permanente of Northern California, Oakland, CA, USA, ⁹MassGeneral Hospital for Children, Boston, MA, USA

P-0050. Hand-assisted laparoscopic surgery for Inflammatory Bowel Disease: Short-term outcomes in 376 patients

Holubar S, Pendlimari R, Pattan-arun J, Larson D, Dozois E, Pemberton J, Cima R
Division of Colon and Rectal Surgery, Mayo Clinic Rochester MN, USA

P-0051. Primary intestinal Lymphoma in patients with Inflammatory Bowel Disease: Clinicopathological features and long-term survival

Holubar S¹, Dozois E¹, Loftus Jr. E², Teh S¹, Benavente L¹, Harmsen W³, Wolff B¹, Larson D¹

¹Division of Colon and Rectal Surgery; Mayo Clinic; Rochester, MN, USA, ²Division of Gastroenterology and Hepatology, Mayo Clinic; Rochester, MN, USA, ³Division of Biomedical Statistics and Informatics; Mayo Clinic; Rochester, MN, USA

P-0052. Do outcomes differ after 3-Stage versus 2-Stage Ileal Pouch-Anal Anastomosis for chronic Ulcerative Colitis?

Holubar S, Pendlimari R, Dy B, Pattan-arun J, Larson D, Dozois E, Pemberton J, Cima R
Division of Colon and Rectal Surgery, Mayo Clinic, Rochester, MN, USA

P-0053. Can bedside criteria predict complications after Ileal Pouch-Anal Anastomosis for chronic Ulcerative Colitis?

Holubar S, Dy B, Pendlimari R, Pattan-arun J, Larson D, Dozois E, Pemberton J, Cima R
Division of Colon and Rectal Surgery, Mayo Clinic, Rochester, MN, USA

P-0054. IBD in Hispanics and Caucasians: Disease characteristics and treatment

Hou J, El-Serag H, Sellin J, Thirumurthi S
Baylor College of Medicine, Houston, TX, USA

P-0055. Daily dosing of delayed release Mesalamine prior to immunosuppressive use

Katz S¹, Pasquale M²

¹Nassau Gastroenterology Associates, P.C., Great Neck, NY, USA, ²Procter & Gamble Pharmaceuticals, Mason, OH, USA

P-0056. Patient perceptions of the impact of Ulcerative Colitis in daily life

Katz S¹, Hershberger M²

¹Nassau Gastroenterology Associates, P.C., Great Neck, NY, USA, ²Procter & Gamble Pharmaceuticals, Mason, OH, USA

P-0057. Ulcerative Colitis in Singapore: Epidemiology and clinical features

Lim K, Kwek A, Fock K, Teo E, Ong J, Ang T, Tan J, Ang J
Changi General Hospital, Singapore, Singapore

P-0058. Distal Ileal Crohn's Disease: The time course of the development of stenosis and obstruction.

Limketkai B¹, Bayless T¹, Ginsburg P², Levine E³, Schwartz J⁴, Montgomery E¹, Hamilton S⁵, Kwon J¹

¹ Johns Hopkins University, Baltimore, MD, USA, ²Hamden, CT, USA, ³Ohio State University Medical Center, Columbus, OH, USA, ⁴Spring Valley, NY, USA, ⁵University of Texas M. D. Anderson Cancer Center, Houston, TX, USA

P-0059. Patterns and predictors of dosage increase in patients treated with Adalimumab for Crohn's Disease in the United States

Loftus Jr E¹, Pan X², Zurawski P³, Chao J³, Mulani P³

¹Miles & Shirley Fiterman Center for Digestive Diseases, Mayo Clinic, Rochester, NY, USA, ²University of Iowa, Iowa City, IA, USA, ³Abbott Laboratories, Abbott Park, IL, USA

P-0060. Describing Characteristics and Chronology of Ulcerative Colitis in African Americans

Malik T, Oster R, Eckhoff A, Gutierrez A

University of Alabama at Birmingham, AL, USA

P-0061. Description and comparison of Crohn's Disease and Ulcerative Colitis in African Americans

Malik T, Oster R, Eckhoff A, Gutierrez A

University of Alabama at Birmingham, AL, USA

P-0062. BMI, Surgical Intervention and Methotrexate use impact Mucosal Disease in African Americans with Crohn's Disease

Malik T, Oster R, Eckhoff A, Peter S, Alexandra G

University of Alabama at Birmingham, AL, USA

P-0063. Corticosteroid use impacts Mucosal Disease Activity in African Americans with Ulcerative Colitis

Malik T, Oster R, Eckhoff A, Peter S, Gutierrez A

University of Alabama at Birmingham, AL, USA

P-0064. Racial disparities in utilization of specialist care and medications in inflammatory bowel disease

Nguyen G¹, LaVeist T², Harris M¹, Wang M¹, Datta L¹, **Brant S¹**

¹Johns Hopkins University School of Medicine, Baltimore, MD, USA, ²Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA

P-0065. Impact of Ileal Pouch-anal Anastomosis surgery on the outcome of orthotopic liver transplantation for primary Sclerosing Cholangitis

Obusez E^{1,2}, Lian L², Robert O², Bo S²

¹Cleveland Clinic Lerner College of Medicine, Cleveland, OH, USA, ²Digestive Diseases Institute

P-0066. Tuberculin skin test in a group of IBD patients from Brazil

Puig I¹, Santana G², Teles M², Gotardo D², Silva N², Paes I²

¹Bahiana School of Medicine and Public Health, Salvador, BA (Brazil), ²General Hospital Roberto Santos

P-0067. IBD and vaccine preventable diseases

Salehi V, Sockolow R, Gagliardo C

Cornell New York Presbyterian Hospital, New York, USA

P-0068. Natalizumab reduces the rate of hospitalization in moderate to severe Crohn's Patients: Evidence from the Clinical Trial Program

Sands B¹, Siegel C², Sandborn W³, Feagan B⁴, Hass S⁵, Nag A⁶, Niecko T⁷

¹Massachusetts General Hospital, Boston, MA, USA, ²Dartmouth-Hitchcock Medical Center, Lebanon, NH, USA,

³Mayo Clinic, Rochester, MN, USA, ⁴Robarts Research Institute, University of Western Ontario, London, Ontario,

CAN, ⁵formerly of Elan Pharmaceuticals, South San Francisco, CA, USA, ⁶Elan Pharmaceuticals, South San

Francisco, CA, USA, ⁷Niecko Health Economics, Escondido, CA, USA

P-0069. Five-year incidence of surgery in a prospectively followed cohort of pediatric patients with Crohn's Disease

Schaefer M^{1,2}, Machan J^{3,4}, Kawatu D³, Langton C^{1,5}, Markowitz J^{1,6}, Crandall W^{1,7}, Mack D^{1,8}, Evans J^{1,9}, Pfefferkorn M^{1,10}, Griffiths A^{1,11}, Otley A^{1,12}, Bousvaros A^{1,13}, Kugathasan S^{1,14}, Rosh J^{1,15}, Keljo D^{1,16}

¹Pediatric Inflammatory Bowel Disease Collaborative Research Group, Hartford, CT, USA, ²Penn State Hershey Medical Center, Penn State Children's Hospital, Hershey, PA, USA, ³Alpert School of Medicine at Brown, Hasbro Children's Hospital, The Rhode Island Hospital, Providence, RI, USA, ⁴Biostatistics, Rhode Island Hospital, Providence, RI, USA, ⁵Connecticut Children's Medical Center, Hartford, CT, USA, ⁶North Shore Long Island Jewish Health System, New Hyde Park, NY, USA, ⁷Nationwide Children's Hospital, Columbus, Ohio, USA, ⁸Children's Hospital of Eastern Ontario, Ottawa, Canada, ⁹Nemours Clinic, Jacksonville, FL, USA, ¹⁰Riley Hospital for Children, Indianapolis, IN, USA

P-0070. Fiber as protective factor for colon polyps

Tantamango Y¹, Knutsen S², Sabate J³

¹Department of Epidemiology and Biostatistics, School of Public Health. Loma Linda University. Loma Linda, CA, USA., ²Department of Epidemiology and Biostatistics, School of Public Health. Loma Linda University. Loma Linda, CA, USA, ³Department of Nutrition, School of Public Health. Loma Linda University. Loma Linda, CA, USA

P-0071. Ten Year coronary heart disease risk among IBD Patients

Yarur A¹, Sussman D², Deshpande A², Damas O¹, Abreu M²

¹Department of Medicine, Jackson Memorial Hospital/University of Miami, Miami, FL, USA, ²Division of Gastroenterology, University of Miami Miller School of Medicine, Miami, FL, USA

P-0072. PEG component of certolizumab pegol inhibits stimulated mast cell degranulation

Lamour S, Bracher M, Nesbitt A

Inflammation Discovery, UCB, Slough, UK

P-0073. Small bowel epithelial gaps and intestinal permeability in Crohn's disease

Liu J, Fedorak R, Dieleman L, Meddings J

Department of Medicine, University of Alberta, Edmonton, Canada

P-0074. Accelerated DNA Damage Response in Inflammatory Bowel Disease: A molecular basis for Cellular Senescence and Cancer Susceptibility

Sohn J¹, Yfantis H², Hussain S¹, Khan M¹, Goto A¹, Bowman E¹, Hofseth L³, Wogan G⁴, Harris C¹

¹Laboratory of Human Carcinogenesis, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA, ²Pathology and Laboratory Medicine, Baltimore Veterans Affairs Medical Center, and Department of Pathology, University of Maryland School of Medicine, Baltimore, MD, USA, ³Department of Pharmaceutical and Biomedical Sciences, South Carolina College of Pharmacy, Columbia, SC, USA, ⁴Department of Biological Engineering, Center for Environmental Health Sciences, Massachusetts Institute of Technology, Cambridge, MA, USA.

P-0075. Smoking, cyclo-oxygenase-2 (COX-2) gene polymorphisms and risk of Inflammatory Bowel Disease in a Scottish and a Danish case-control study

Andersen V¹, Nimmo E², Krarup H³, Drummond H², Christensen J⁵, Ho G², Østergaard M¹, Ernst A³, Lees C², Jacobsen B³, Satsangi J², Vogel U⁴

¹Viborg, Denmark, ²Edinburgh, Skotland, ³Aalborg, Denmark, ⁴Søborg, Denmark, ⁵Copenhagen, Denmark

P-0076. Association of the nuclear receptors PXR, LXR and PPAR γ with ulcerative colitis in the Danish population: A case-control study

Andersen V¹, Christensen J², Østergaard M¹, Jacobsen B³, Ernst A³, Krarup H³, Vogel U⁴

¹Viborg, Denmark, ²Copenhagen, Denmark, ³Aalborg, Denmark, ⁴Søborg, Denmark

P-0077. Gene polymorphisms in Interleukin 1 β , Interleukin 10, and heme oxygenase-1 are not associated with risk of Inflammatory Bowel Disease in the Danish population: A case-control study

Andersen V¹, Christensen J², Jacobsen B³, Ernst A⁵, Østergaard M¹, Krarup H⁵, Vogel U⁴

¹Viborg Regional Hospital, Viborg, Denmark, ²Danish Cancer Society, Copenhagen, Denmark, ³Department of Medical Gastroenterology, Aalborg, Denmark, ⁴National Food Institute, Søborg, Denmark, ⁵Department of Clinical Biochemistry, Aalborg, Denmark

P-0078. NOD2 and TNF alpha Gene polymorphisms in Korean pediatric patients with Inflammatory Bowel Disease

Jang J¹, Lee Y², Kim K²

¹Ajou University School of Medicine, Department of Pediatrics, Suwon, South Korea, ²Asan Medical Center Children's Hospital, Department of Pediatrics, Asan, South Korea

P-0079. Early onset Crohn's Disease is associated with male gender and a polymorphism in the IL 6 promoter
Levine A¹, Sagiv K¹, Karban A², Leshinsky-Silver E³

¹Pediatric gastroenterology Unit, Wolfson Medical Center, Holon, Israel, ²Gastroenterology Division, Rambam Medical Center, Haifa, Israel, ³Molecular Biology Lab, Wolfson Medical Center, Israel

P-0080. Predictive testing for Inflammatory Bowel Diseases: The views of unaffected siblings

Mindlin A^{1,2}, Shuman C^{1,2}, **Walters T³**, Chitayat D^{1,2}, Popalis C³, Reif S⁴, Frost K³, Wright M³, Griffiths A³

¹Department of Molecular Genetics, University of Toronto, Toronto, Canada, ²Division of Clinical and Metabolic Genetics, Hospital for Sick Children, Toronto, Canada, ³Division of Gastroenterology, Hepatology and Nutrition, Hospital for Sick Children, Toronto, Canada, ⁴Dana's Children's Hospital, Pediatric GI unit, Tel Aviv University, Tel Aviv, Israel

P-0081. Genes regulated by Nkx2-3 in a B cell line from a Crohn's disease patient

Yu W¹, Lin Z¹, Hegarty J¹, Chen X³, Faber P⁴, Kelly A¹, Wang Y¹, Poritz L^{1,2}, Schreiber S⁵, Koltun W¹

¹Department of Surgery, Pennsylvania State University College of Medicine, Hershey, PA, USA, ²Department of Cellular & Molecular Physiology, Pennsylvania State University College of Medicine, Hershey, PA, USA, ³Department of Biostatistics, Vanderbilt University School of Medicine, Nashville, TN, USA, ⁴Genomics Core of the Cleveland Clinic Lerner Research Institute, Cleveland, OH, USA, ⁵Institute for Clinical Molecular Biology, Christian-Albrechts University, Kiel, Germany

P-0082. Role of complement and the use of complement Inhibitors in the Acute DSS Model of IBD

Schepp J, Atkinson C, Qiao F, Spearman J, Gilkeson G, Tomlinson S

Medical University of South Carolina, Charleston, SC, USA

P-0083. Comparative analysis of E. Coli associated with Inflammatory Bowel Disease across species

Dogan B¹, **Scherl E²**, Bosworth B², Yantiss R², Volkmann M¹, Oh J¹, Klaessig S¹, Simpson K¹

¹Cornell University, Ithaca, NY, USA, ²Cornell University, New York, NY, USA

P-0084. Adhering and invading E. Coli: Defining the link to Crohn's Disease

Leung N¹, Ossa J², Wine E², Chan C³, Stanners C³, Sherman P², **Gray-Owen S¹**

¹Department of Molecular Genetics, University of Toronto, Toronto, ON, Canada, ²Department of Laboratory Medicine & Pathobiology, University of Toronto, Toronto, ON, Canada, ³McGill University Cancer Centre, Montreal, QC

P-0085. Internet websites selling probiotics marketed to pediatric Crohn's patients have unstudied efficacy

Adham K, Dougherty T, Sardana N, Prakash P, Borum M

George Washington University, Washington, DC, USA

P-0086. Physicians inconsistently screen for depression in Inflammatory Bowel Disease patients

Barocas J, Dougherty T, Adham K, Borum M

George Washington University, Washington, DC, USA

P-0087. Adherence with oral 5-aminosalicylic acid therapy in patients with ulcerative colitis: impact on all-cause healthcare costs

Debanjali M¹, Hodgkins P², Yen L², Solomon D², Davis K², Cohen R³

¹RTI Health Solutions, Research Triangle, NC, USA, ²Shire Pharmaceuticals Inc., USA, ³University of Chicago, IL, USA

P-0088. Physicians inconsistently evaluate Viatmin B12 levels in patients with Crohn's Disease involving the Ileum

Dougherty T, Adham K, Borum M

George Washington University, Washington, DC, USA

P-0089. Physicians inconsistently test folate levels in women with Crohn's Disease who are of child-bearing age

Dougherty T, Adham K, Borum M

George Washington University, Washington, DC, USA

P-0090. Inflammatory Bowel Disease patients infrequently change from multi-dose to single dose Aminosalicylates

Dougherty T, Adham K, Borum M

George Washington University

P-0091. Preliminary outcomes from the MMX® mesalamine patient experience program in patients with ulcerative colitis

Hamilton T¹, Patel N¹, Sumner M¹, Solomon D¹, Kerney D²

¹Shire Pharmaceuticals Inc., Wayne, PA, USA, ²InfoMedics Inc.

P-0092. Induction of clinical and endoscopic remission in mild-to-moderate ulcerative colitis in patients treated with MMX® mesalamine: established versus newly diagnosed disease

Kamm M¹, Sandborn W², Lichtenstein G³, Solomon D⁴, Karlstadt R⁴, Barrett K⁴, Abhyankar B⁴

¹St Vincent's Hospital, Melbourne, Australia, ²Mayo Clinic, Rochester, MN, USA, ³University of Pennsylvania, Philadelphia, PA, USA, ⁴Shire Pharmaceuticals Inc., Wayne, PA, USA

P-0093. Long-term persistence with ulcerative colitis medication: results in patients persistent with therapy at outset

Kane S¹, Sumner M², Solomon D², Jenkins M²

¹Mayo Clinic, Rochester, MN, USA, ²Shire Pharmaceuticals Inc., USA

P-0094. Continued persistence with mesalamine therapy in long-term persistent patients: Results from a large pharmacy database

Kane S¹, Sumner M², Solomon D², Jenkins M²

¹Mayo Clinic, Rochester, MN, USA, ²Shire Pharmaceuticals Inc., USA

P-0095. Factors influencing persistence with mesalamine therapy: Results from a large pharmacy database

Kane S¹, Sumner M², Solomon D², Jenkins M²

¹Mayo Clinic, Rochester, MN, USA, ²Shire Pharmaceuticals Inc., USA

P-0096. Induction of mucosal healing in mild-to-moderate ulcerative colitis in patients treated with MMX® mesalamine: established versus newly diagnosed disease

Lichtenstein G¹, Sandborn W², Kamm M³, Solomon D⁴, Karlstadt R⁴, Barrett K⁴, Abhyankar B⁴

¹University of Pennsylvania, Philadelphia, PA, USA, ²Mayo Clinic, Rochester, MN, USA, ³St Vincent's Hospital, Melbourne, Australia, ⁴Shire Pharmaceuticals Inc., Wayne PA, USA

P-0097. Influenza and pneumococcal immunization in Inflammatory Bowel Disease patients

Okoji O, Nguyen H, Borum M

George Washington University, Washington, DC, USA

P-0098. Gastroenterologists infrequently refer patients on steroids for ophthalmology evaluations

Sardana N, Prakash P, Borum M

George Washington University, Washington, DC, USA

P-0099. Physicians infrequently address the pregnancy concerns of women with Inflammatory Bowel Disease

Shafa S, Borum M

George Washington University, Washington, DC

P-0100. Gastrointestinal-related diagnostic procedures in patients with Inflammatory Bowel Disease before and after Infliximab Initiation

Vanderpoel J¹, Waters H¹, Nejadnik B¹, Lunacsek O², Lennert B², McKenzie R¹

¹Centocor Ortho Biotech Services, LLC, Horsham, PA., USA, ²Xcenda, LLC, Palm Harbor, FL., USA

P-0101. Utilization and surgical procedures following Colectomy in patients with Ulcerative Colitis

Waters H¹, Van Den Bos J², Piech C¹

¹Centocor Ortho Biotech Services, LLC, Horsham, PA., USA, ²Milliman, Inc., Denver, CO., USA

P-0102. A Case of Esophageal Crohn's Disease

Sharma T, Agrawal R

Allegheny General Hospital, Pittsburgh, PA, USA

P-0103. Investigation of potential early histologic markers of pediatric Inflammatory Bowel Disease

Bass J, Drews A, Friesen C, Geraghty C, San Pablo W, Singh V

Children's Mercy Hospital, Kansas City, MO

P-0104. Lymphocytic esophagitis in pediatric inflammatory bowel disease: A manifestation of upper gastrointestinal Crohn disease.

Ebach D¹, Vanderheyden A², Ellison J³, Jensen C⁴

¹University of Iowa, Iowa City, IA, USA, ²Bedford, OH, USA, ³Idaho Pediatric Gastroenterology, Boise, ID, USA,

⁴University of Iowa, Iowa City, IA, USA

P-0105. Ultrasound evaluation of Inflammatory Bowel Disease

Ebbert T, Abu-Yousef M

University of Iowa Hospitals and Clinics, Iowa City, IA, USA

P-0106. A new rapid home test for Faecal Calprotectin measurement by a mobile phone is reliable

Elkjaer M¹, **Svendsen A**¹, Laugesen B², Burisch J¹, Voxen Hansen V¹, Deibjerg Kristensen B¹, Munkholm P¹

¹Herlev University Hospital, Copenhagen, Denmark, ²Amager Hospital, Copenhagen, Denmark

P-0107. Leukocyte GM-CSF Receptor (CD116) Expression as a distinguishing biomarker for Inflammatory Bowel Disease (IBD)

Goldstein J, Jacobson N, Bowers B, Austin G, Golden-Mason L, Colgan S

Mucosal Inflammation Program and Division of Gastroenterology and Hepatology, University of Colorado Denver, Aurora, CO, USA

P-0108. Comparative effectiveness of PetCT in IBD

Lapp R¹, Spier B², Reichelderfer M², Perlman S³

¹Department of Internal Medicine, University of Wisconsin Hospital and Clinics in Madison, Wisconsin, USA,

²Department of Gastroenterology and Hepatology, University of Wisconsin Hospital and Clinics in Madison, Wisconsin, USA, ³Department of Radiology, University of Wisconsin Hospital and Clinics in Madison, Wisconsin, USA

P-0109. Do we need patient schools?

Laugesen B

Amager Hospital, Copenhagen, Denmark

P-0110. Fecal calprotectin in Inflammatory Bowel Disease treated with anti-TNF agents

Marzo M¹, Armuzzi A¹, Felice C¹, Forni F², Papa A¹, De Vitis I¹, Guidi L¹

¹Internal Medicine, Università Cattolica del Sacro Cuore, Rome Italy, ²Laboratory Medicine, Università Cattolica del Sacro Cuore, Rome, Italy

P-0111. 5-ASA Therapy in the elderly IBD patients: Risk vs. Benefits

Mogul Z, Feldstein R, Katz S

North Shore University Hospital, Manhasset, NY, USA

P-0112. Evaluation of a novel pre-filled syringe for self-administration of certolizumab pegol: results from a syringe usability study

Schiff M¹, Sheikhzadeh A², Formosa D³, Domanska B⁴, Morgan D⁴

¹University of Colorado School of Medicine, Denver, CO, USA, ²NYU-Hospital for Joint Disease, New York University, NY, USA, ³Smart Design, New York, NY, USA, ⁴UCB Celltech, Slough, UK

P-0113. Mobile and Web-Based Application for IBD Tracking

Shafran I¹, Burgunder P¹, Shamosh B²

¹Shafran Gastroenterology Center, Winter Park, FL, USA, ²WellApps, Inc., USA

P-0114. Adalimumab in Crohn's Disease patients to maintain surgically-induced remission: Can fecal calprotectin predict postoperative recurrence?

Fernandez-Blanco I¹, Martinez B², Codoceo R³, Monturiol J⁴, Garcia-Montes M¹, Cara C¹

¹IBD Unit. Hospital Moncloa. Madrid, Spain, ²Nuclear Medicine Dpt. Hospital La Paz, Madrid, Spain,

³Gastroenterology General Laboratory. Hospital La Paz, Madrid, Spain, ⁴Surgery Dpt. Hospital Gregorio Marañon, Madrid, Spain

P-0115. Poor growth in Crohn's Disease is caused by low IGF-1 Levels

Hardin D

The Ohio State University/nationwide Childrens Research Institute, Columbus, OH, USA

P-0116. Clinical cases of Crohn's Disease in Familial Mediterranean Fever

Injigulyan K, Yeganyan G, Yeganyan E

Erevan State Medical University, Erevan, Armentia

P-0117. Adalimumab Therapy maintains meaningful rates of steroid-free remission in patients with Crohn's Disease for up to 3 Years of Therapy: Results From an Open-Label Extension of CHARM

Kamm M¹, Hanauer S², Panaccione R³, Colombel J⁴, Sandborn W⁵, Lomax K⁶, Pollack P⁶

¹St Vincent's Hospital and University of Melbourne, Melbourne, Australia, ²University of Chicago, Chicago, IL, USA,

³University of Calgary, Calgary, AB, Canada, ⁴Hôpital Claude Huriez, Centre Hospitalier Universitaire de Lille, Lille, France, ⁵Mayo Clinic, Rochester, MN, USA, ⁶Abbott Laboratories, Abbott Park, IL, United States

P-0118. Adalimumab Therapy reduces the presence of Extraintestinal Manifestations in patients with Crohn's Disease: The CARE Trial

Louis E¹, Lofberg R², Reinisch W³, Kron M⁴, Camez A⁴, Robinson A⁵, Pollack P⁵

¹University of Liège, Liège, Belgium, ²Karolinska Institutet, Stockholm, Sweden, ³Medical University of Vienna, Vienna, Austria, ⁴Abbott GmbH & Co. KG, Ludwigshafen, Germany, ⁵Abbott Laboratories, Abbott Park, IL, United States

P-0119. Safety and efficacy of Adalimumab for the induction of remission in Crohn's Disease in a specialist nurse lead outpatient clinic: Preliminary data from a single centre prospective study

Martinato M, Slogno T, Oliva L, Caccaro R, Sturniolo G, D'Inca R

Azienda Ospedaliera - Università di Padova, Padova, Italy

P-0120. Intravaginal estrogen: A non-operative treatment for chronic rectovaginal fistula

Otterson M¹, Lundeen S¹, Sudakoff G¹, Binion D²

¹Medical College of WI, Milwaukee, WI, USA, ²University of Pittsburg, Pittsburg, PA, USA

P-0121. Adalimumab Therapy maintains remission for up to 3 Years in patients with moderately to severely active Crohn's Disease: Results From an Open-Label Extension of CHARM

Panaccione R¹, Colombel J², Sandborn W³, Rutgeerts P⁴, D'Haens G⁵, Lomax K⁶, Li J⁶, Pollack P⁶

¹University of Calgary, Calgary, AB, Canada, ²Hôpital Claude Huriez, Centre Hospitalier Universitaire de Lille, Lille, France, ³Mayo Clinic, Rochester, MN, United States, ⁴University Hospital of Gasthuisberg, Leuven, Belgium, ⁵Imelda GI Clinical Research Center, Bonheiden, Belgium, ⁶Abbott Laboratories, Abbott Park, IL, United States

P-0122. Adalimumab Therapy maintains steroid-free remission and Fistula Closure in patients with moderate to severe Crohn's Disease: Results of an Open-Label Study in Canada (ACCESS)

Panaccione R¹, Loftus Jr E², Binion D³, McHugh K⁴, Chen N⁵, Chao J⁵, Mulani P⁵

¹University of Calgary, Calgary, AB, Canada, ²Miles & Shirley Fiterman Center for Digestive Diseases, Mayo Clinic, Rochester, MN, United States, ³University of Pittsburgh, Pittsburgh, PA, United States, ⁴Abbott Laboratories, St. Laurent, QC, Canada, ⁵Abbott Laboratories, Abbott Park, IL, United States

P-0123. Outcomes of salvage therapy for acute severe ulcerative colitis: Cyclosporin versus Infliximab

Radford-Smith G^{1,2}, Croft A¹, Doecke J², Walsh A³

¹Department of Gastroenterology, Royal Brisbane and Women's Hospital, Brisbane, Australia, ²Queensland Institute of Medical Research, Brisbane, Australia, ³Department of Gastroenterology, St Vincent's Hospital, Sydney, New South Wales, Australia

P-0124. Time to clinical effect of Sub-Cutaneous Methotrexate in Pediatric Crohn's Disease

Rosh J, Fingerhut L, Langseder A, Irizarry R

Pediatric Gastroenterology, Goryeb Children's Hospital at Atlantic Health

P-0125. Oral B12 in Crohn's Disease: Is B12 by injection obsolete?

Saibil F^{1,2}, Morgan M²

¹University of Toronto, Toronto, On, Canada, ²Sunnybrook HSC, Toronto, On, Canada

P-0126. Adalimumab Therapy for Patients With Crohn's Disease Who Are Unresponsive to or Intolerant of Infliximab

Shafran I, Burgunder P, Fakhri A

Shafran Gastroenterology Center, Winter Park, FL, U.S.A.

P-0127. Long-term Rifaximin Treatment for Newly Diagnosed Crohn's Disease

Shafran I, Burgunder P

Shafran Gastroenterology Center, Winter Park, FL, USA

P-0128. Pain and pain catastrophizing in pediatric Inflammatory Bowel Disease

Sicard M, Campbell C, Oliva-Hemker M, Haythornthwaite J

Johns Hopkins University, Baltimore, MD

P-0129. Clinical usefulness and problems of maintenance therapy with Infliximab in patients with Crohn's Disease

Yokoyama K, Kobayashi K, Mukae M, Yamagata M, Fukushima H, Sada M

Kitasato University East Hospital, Sagami-hara, Japan

P-0130. Relevance of biologic markers to diagnose Inflammatory Bowel Diseases

Auclair M, D'Aoust E, Lahaie R

Montreal University, Montréal, Québec, Canada

P-0130-A. Distinct DNA methylation patterns as biomarkers for dysplasia in patients with ulcerative colitis
Scherr R, Tang W, Barwick B, Bouzyk M, Kugathasan S
Emory University School of Medicine, Atlanta, GA, USA

TABLE OF CONTENTS

BASIC SCIENCE

O-0008. HIF-dependent regulation of platelet-activating factor receptor (PAFr) as a route for Gram positive bacterial translocation across epithelia

Keely S, Glover L, Weissmueller T, MacManus C, Fennimore B, Colgan S
Mucosal Inflammation Program, University of Colorado Denver, Aurora, CO, USA

O-0009. Expansion of CCR9+ Lymphocytes in Crohn's Disease and Murine Ileitis Associated with Granulocyte-Macrophage Colony Stimulating Factor Auto-Antibodies

Samson C¹, Jurickova I¹, Schreiner W^{1,2}, Bonkowski E¹, Koch D³, Trapnell B³, Denson L¹
¹Gastroenterology, Hepatology & Nutrition; Cincinnati Children's Hospital Medical Center; Cincinnati, OH, USA, ²University of North Carolina at Chapel Hill; Chapel Hill, NC, USA, ³Department of Pulmonary Biology; Cincinnati Children's Hospital Medical Center; Cincinnati, OH, USA

O-0010. TLR2-mediated control of gap junctional intercellular communication essentially contributes to intestinal epithelial barrier homeostasis during acute and chronic colitis

Ey B¹, Eyking A¹, Gerken G¹, Podolsky D², **Cario E**¹
¹Div. of Gastroenterology, Univ Hosp Essen, Medical School, Univ Duisburg-Essen, Essen, Germany, ²UT Southwestern Medical Center, Dallas, TX, USA.

O-0011. CCR9 Inhibition in the treatment of Colonic Inflammation

Walters M, Berahovich R, Ertl L, Ebsworth K, Baumgart T, Charvat T, Powers J, Punna S, Wang Y, Bekker P, Jaen J, Schall T
Chemocentryx Inc, Mountain View, CA, USA

O-0012. Early-onset inflammatory bowel disease caused by loss-of-function mutations in the IL10-receptor genes

Glocker E¹, Kotlarz D², Boztug K², Gertz E³, Schaffer A³, Koletzko S⁴, Shah N⁵, Segal A⁶, Snapper S⁷, Grimbacher B¹, Klein C²
¹Department of Immunology, Royal Free Hospital and University College London, London, UK, ²Department of Pediatric Hematology/Oncology, Hannover Medical School, Hannover, Germany, ³National Center for Biotechnology Information, NIH, DHHS, Bethesda, MD, USA, ⁴Dr. von Hauner'sches Kinderspital, Ludwig-Maximilian University, Munich, Germany, ⁵Department of Paediatric Gastroenterology, Great Ormond Street Hospital, UCL, London, UK, ⁶Department of Medicine, University College London, London, UK, ⁷Massachusetts General Hospital, Harvard Medical School, Boston MA, USA

P-0131. CD26+ Lymphocytes and serum soluble CD26/ Dipeptidyl peptidase IV are involved in the Pathogenesis of Crohn's Disease

Inoue N¹, Hisamatsu T², Takayama T², Okamoto S², Ogata H¹, Iwao Y¹, Yamada T³, Hosono O⁴, Morimoto C⁴, Hibi T²
¹Center for Diagnostic and Therapeutic Endoscopy, Keio University School of Medicine, Tokyo, Japan, ²Division of Gastroenterology and Hepatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan, ³Department of Pathology, Keio University School of Medicine, Tokyo, Japan, ⁴Department of Clinical Immunology, Advanced Clinical Research Center, Institute of Medical Science, University of Tokyo, Tokyo, Japan

P-0132. Control of inflammatory bowel disease by regulating vitamin A intake: Roles of distinct regulatory T cell subsets

Kim C, Kang S, Wang C
Department of Comparative Pathobiology, Purdue University, West Lafayette, IN, USA

P-0133. The effect of $\alpha 4\beta 7$ blockade on T-lymphocyte trafficking to intestinal compartments in the normal and inflamed intestine

Wang C, Hanly E, McDonald K, Newberry R
Washington University School of Medicine, St. Louis, MO, USA

P-0134. Dual effects of OX40 on different T Cell subset activation and consequent DSS-induced Colitis

Zhang Z¹, Zhong W¹, Wegmann K², Hinrichs D²

¹Oregon Health & Science University, Portland, OR, USA, ²Portland VA Medical Center, Portland, OR, USA

P-0135. Temporal global expression profiling of DSS colitis and identification of potential targets of ulcerative colitis

Fang K¹, Bruce M¹, Pattillo C¹, Bao J¹, Zhang S¹, Stone R², Clifford J², Kevil C¹

¹Department of Pathology, Louisiana State University Health Science Center- Shreveport, LA, USA, ²Department of Biochemistry and Molecular Biology, Louisiana State University Health Science Center- Shreveport, LA, USA

P-0136. Blood flow rate in a T-cell transfer model of Inflammatory Bowel Disease in mice

Harris N, Carter P, Lee S, Watts M, Zhang S, Grisham M

LSU Health Sciences Center, Shreveport, LA, USA

P-0137. Mouse video endoscopy: A novel method in the preclinical development of Inflammatory Bowel Disease therapies

Lyng G¹, Stevens C¹, Watkins B¹, Fey E¹, Sonis S^{1,2}

¹Biomodels LLC, Watertown, MA, USA, ²Brigham and Women's Hospital, Boston, MA, USA

P-0138. Eosinophil reduction attenuates remodeling in Samp1 mice

Masterson J^{1,2,5}, McMamee E^{2,3,5}, Jedlicka P^{4,5}, Lee J⁶, Fillon S^{1,2,5}, Rivera-Nieves J^{2,3,5}, Furuta G^{1,2,5}

¹Section of Pediatric Gastroenterology, Hepatology & Nutrition, The Childrens Hospital, Aurora, Gastrointestinal Eosinophilic Diseases Program, Aurora, CO, USA, ²Mucosal Inflammation program, Aurora, CO, USA, ³Division of Gastroenterology, Aurora, CO, USA, ⁴Department of Pathology, Aurora, CO, USA, ⁵UC Denver, School of Medicine, Aurora, CO, USA, ⁶Department of Biochemistry and Molecular Biology, Mayo Clinic Scottsdale, Scottsdale, AZ, USA

P-0139. Tumor necrosis factor receptor signaling in intestinal epithelia may be directly involved in colitis-associated carcinogenesis

Nagaishi T, Onizawa M, Wang S, Suzuki M, Tsuge N, Yamaji O, Totsuka T, Watanabe M

Tokyo Medical and Dental University, Tokyo, Japan

P-0140. Thrombospondin 1 regulates interleukin 6 by an angiogenic mechanism mediated by TGFbeta1

Nye D^{1,2}, Lopez-Dee Z¹, Simone C¹, Papathomas K¹, Ling J², Gutierrez L¹

¹Department of Biology, Wilkes University, Wilkes-Barre, PA, USA, ²Basic Basic Sciences Department, The Commonwealth Medical School, Scranton, PA, USA.

P-0141. Comparison of the distribution of an IgG and a PEGylated Fab' form of an anti-TNF- α antibody in the inflamed gut of colitic mice

Eddleston A, Marenzana M, Marshall D, Nesbitt A

Inflammation Discovery, UCB, Slough, UK

P-0144. Regional immunomodulation of the gastrointestinal tract without systemic immunosuppression in Cynomolgus macaques by vedolizumab.

Fedyk E¹, Yang L², Csizmadia V¹, Yang H³, Wyant T², Kadambi V¹, Alden C¹

¹Drug Safety and Evaluation, Millennium Pharmaceuticals Inc., Cambridge, MA, USA, ²Molecular Medicine, Millennium Pharmaceuticals Inc., Cambridge, MA, USA, ³Drug Metabolism and Pharmacokinetics, Millennium Pharmaceuticals Inc., Cambridge, MA, USA

P-0145. Novel Guggulsterone Derivative GG-52 inhibits NF- κ B Signaling in Intestinal Epithelial Cells and attenuates acute Murine Colitis

Kang H¹, Kim J², Cha M², Lee J², Kim N³, Kim I³, Ku J⁴, Kim S⁴, Ma S⁵, Jung H³, Song I³, Kim J³

¹Department of Internal Medicine, Dongguk University College of Medicine, Goyang, South Korea, ²Department of Microbiology, Hanyang University College of Medicine, South Korea, ³Department of Internal Medicine and Liver Research Institute, Seoul National University College of Medicine, Seoul, South Korea, ⁴Department of Biomedical Engineering, Hanyang University, Seoul, South Korea, ⁵Central Research Institute, Choongwae Pharma Co. Hwasung, South Korea

P-0146. L-arginine attenuates interleukin-1 induced NF-KB activation in Caco-2 cells

Meng Q, Pan M, Cooney R

Penn State M.S. Hershey Medical Center, Hersey, PA, USA

P-0147. Significant decrease of mucosal cytoglobin+ pericryptal myofibroblasts in long-standing ulcerative colitis with colorectal neoplasia, correlatively with alpha-SMA and HSP47 phenotypic expression

Okayasu I¹, Fujiwara M³, Yoshida T¹, Mikami T¹, Hana K¹, Yokozawa M¹, Sada M², Kawada N⁴

¹Dept of Pathology, Kitasato University School of Medicine, Sagamihara, Japan, ²Dept of Gastroenterology, Kitasato University School of Medicine, Kitasato, Japan, ³Dept of Clinical Pathology, Japanese Red Cross Medical Center, Japan, ⁴Dept of Hepatology, Graduate School of Medicine, Osaka City University, Osaka City, Japan

P-0148. Afro-Caribbeans and Hispanic-Americans have distinct Phenotypic Manifestations of Inflammatory Bowel Disease when compared to Caucasians or African-Americans

Damas O, Jahann D, Smith C, Deshpande A, Sussman D, Tamariz L, Abreu M

University of Miami Miller School of Medicine/Jackson Memorial Hospital, Miami, FL, USA

P-0149. Interleukin-10 selectively regulates HIF-1 α function in intestinal epithelial cells through regulated expression of HIF Prolyl Hydroxylases

Gerich M, Kominsky D, Scully M, Colgan S

University of Colorado Denver, Aurora, CO, USA

P-0150. The mechanisms of enhanced paracellular permeability in the small intestine of MTX-treated rats

Hamada K, Shitara Y, Sekine S, Horie T

Department of Biopharmaceutics, Graduate School of Pharmaceutical Sciences, Chib

P-0152. The protective role of HNF4 α in an intestinal epithelial cell model and the exploration of its genetic polymorphisms in inflammatory bowel diseases

Marcil V¹, Seidman E^{1,2}, Amre D³, Boudreau F², Gendron F², Asselin C², Beaulieu J², Sinnott D³, Levy E^{2,4}

¹Research Institute of McGill University Health Center, Montreal, Canada, ²CIHR Research Group on the Digestive Epithelium, Department of Anatomy and Cellular Biology, Faculty of Medicine and Health Sciences, Université de Sherbrooke, Sherbrooke, Quebec, Canada, ³Department of Pediatrics, Université de Montreal, CHU Sainte-Justine Research Institute, Montreal, Quebec, Canada, ⁴Department of Nutrition, Université de Montreal, CHU Sainte-Justine Research Institute, Montreal, Quebec, Canada

P-0153. IL-27 mediates STAT1/STAT3 activation in human intestinal epithelial cells and regulates IL-8, IL-6 and wound healing

Tian X¹, Rajendra C¹, Scherr R¹, Sitaraman S², Kugathasan S¹

¹Division of Pediatric Gastroenterology, Hepatology and Nutrition, Department of Pediatrics, Emory University School of Medicine, Atlanta, GA, USA, ²Division of Gastroenterology, Department of Medicine, Emory University School of Medicine, Atlanta, GA, USA

P-0154. Quantitative analysis of small bowel epithelial gaps in IL-10 knockout and control 129 Sv/Ev mice

Liu J¹, Boulanger P², Madsen K¹, Fedorak R¹, Broderick G¹, Meddings J¹

¹Department of Medicine, University of Alberta, Edmonton, Canada, ²Department of Engineering, University of Alberta, Edmonton, Canada

P-0155. Functional consequences of autophagy gene mutations in human intestinal epithelial cells

Boone D, Messer J, Logsdon M, Lodolce J, Bartulis S, Kolodziej L, Schneider J, Dougherty U, Bissonnette M

The University of Chicago, Department of Medicine. Chicago, IL, USA

P-0156. Identification and characterization of genes associated with IBD on chromosomal region 1q32

David G^{1,2}, Budarf M², Charron G², Bitton A³, Rioux J^{1,2}

¹Department of Medicine, Université de Montréal, Montreal, Quebec, Canada, ²Montreal Heart Institute, Montreal, Quebec, Canada, ³Division of Gastroenterology, Royal Victoria Hospital, McGill University, Montreal, Quebec, Canada

P-0158. Mast cell-restricted Trypsases are essential in a Mouse Model of Inflammatory Bowel Disease

Hamilton M¹, Sinnamon M¹, Glickman J¹, Krilis S³, Blumberg R¹, Lee D¹, Adachi R², Stevens R¹

¹Brigham and Women's Hospital, Boston, MA, USA, ²Univ. of Texas, MD Anderson Hospital, Houston, TX, USA, ³Univ. of New South Wales, St. George Hospital, Australia

P-0159. The role of ATG16L1 in bacterial-induced autophagy

Hussey S^{1,2,3,4}, Yuan L², Travassos L², Philpott D², Jones N^{1,3,4}

¹Division of Gastroenterology, Hepatology and Nutrition, Hospital for Sick Children, Toronto, Canada, ²Department of Immunology, University of Toronto, Toronto, Canada, ³Departments of Paediatrics and Physiology, University of Toronto, Toronto, Canada, ⁴Cell Biology Programme, Hospital for Sick Children, Toronto, Canada

P-0160. Immunomodulatory peptides attenuate local and systemic inflammation in a murine DSS-colitis model

Mayer M^{1,2,3}, Ivison S^{2,4}, Fjell C^{1,3}, Ma S¹, Himmel M², Steiner T^{2,4}, Hancock R^{1,3}

¹Centre for Microbial Disease and Immunity Research, University of British Columbia, Vancouver, Canada, ²Faculty of Medicine, University of British Columbia, Vancouver, Canada, ³Department of Microbiology and Immunology, University of British Columbia, Vancouver, Canada, ⁴Division of Infectious Diseases, University of British Columbia, Vancouver, Canada

P-0161. Human CD14(+) macrophages in intestinal lamina propria exhibit potent antigen-presenting ability

Okamoto S, Kamada N, Hibi T

Keio University School of Medicine, Tokyo, Japan

P-0162. Bacterial PAMPs regulate PD-L1 expression on colonic myofibroblasts

Pinchuk I¹, Johnson J¹, Beswick E², Saada J¹, Mifflin R¹, Reyes V², Powell D¹

¹University of Texas Medical Branch, Department of Internal Medicine, Galveston, TX, USA, ²University of Texas Medical Branch, Department of Microbiology and Immunology, Galveston, TX, USA

P-0163. The A4-Fla2 flagellin, a dominant antigen in Crohn's Disease, is a poor TLR5 agonist

Steiner T¹, Ivison S¹, Wang C¹, Elson C²

¹University of British Columbia, Vancouver, BC, Canada, ²University of Alabama, Birmingham, AL, USA

P-0164. Sheathed vs. Standard Forceps: Does it matter for obtaining uncontaminated biopsy specimens of microbiota from the terminal ileum?

Dave M¹, Johnson L², Chaudhary M², Funnell J², Stidham R², Walk S³, Young V³, Higgins P²

¹Internal Medicine, Wayne State University, Detroit, MI, USA, ²Div. of Gastroenterology, University of Michigan, Ann Arbor, MI, USA, ³Div. of Infectious Diseases, University of Michigan, Ann Arbor, MI, USA

P-0165. Impact of Escherichia coli colonization on susceptibility to colitic insults: It takes two to tango

Ramer-Tait A¹, Overstreet A¹, Sung C¹, Henderson A¹, Hostetter J², Jergens A³, Wannemuehler M¹

¹Department of Veterinary Microbiology and Preventive Medicine, Iowa State University, Ames, IA, ²Department of Veterinary Pathology, Iowa State University, Ames, IA, ³Department of Veterinary Clinical Sciences, Iowa State University, Ames, IA

P-0166. Guar gum-based colon-specific drug delivery systems for the treatment of Inflammatory Bowel Diseases

Yellela S^{1,2}, S S, YV R

¹College of Pharmacy, Nova Southeastern University, Fort Lauderdale, FL, USA, ²Department of Pharmaceutical Sciences, Andhra University, Visakhapatnam, India

P-0167. The PEG Moiety of Certolizumab Pegol is Rapidly Cleared From the Blood of Humans by the Kidneys Once it is Cleaved From the Fab'

Parton T¹, King L¹, Parker G², Nesbitt A³

¹Research DMPK, UCB Celltech, Slough, UK, ²Clinical Pharmacology, UCB Celltech, Slough, UK, ³Inflammation Discovery, UCB Celltech, Slough, UK

P-0169. Genotypic variation in STAT3 is associated with Increased Cellular STAT3 Activation and up-regulation of Colonic Leukocyte Recruitment Genes in Crohn's Disease

Willson T^{1,2}, Jurickova I¹, Gerad S¹, Bonkowski E¹, Carey R¹, Denson L¹

¹Division of Gastroenterology, Hepatology and Nutrition, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA, ²Cell and Cancer Biology Graduate Program, University of Cincinnati, College of Medicine, Cincinnati, OH, USA

P-0170. Stability of Infliximab dosing in Ulcerative Colitis: Results from a Chart Review

Waters H¹, McKenzie R¹, Lunacsek O², Franklin M², Lennert B², Piech C¹

¹Centocor Ortho Biotech Services, LLC, Horsham, PA., USA, ²Xcenda, LLC, Palm Harbor, FL., USA

P-0171. The Role of TULA Family Proteins in Inflammatory Bowel Disease

Newman T¹, Yen J¹, Ganea D¹, Carpino N², Tsygankov A¹.

¹Department of Microbiology and Immunology, Temple University School of Medicine, Philadelphia PA, USA, ² Department of Molecular Genetics and Microbiology, Room 130, Life Sciences Building, Stony Brook University, Stony Brook, NY, USA